PhagePro develops bacteriophage-based therapeutics to combat antibiotic-resistant infections, specifically targeting diseases like cholera. The company addresses the global health crisis of antibiotic resistance by utilizing phages, which are natural predators of bacteria, to restore effective treatment options.
Funding
$100K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Antibiotic resistance is a growing global health crisis, rendering many bacterial infections increasingly difficult or impossible to treat with conventional antibiotics. This poses a significant threat, particularly in regions where access to advanced medical care is limited and infectious diseases like cholera remain prevalent.
Solution
PhagePro is developing bacteriophage-based therapeutics as an alternative to traditional antibiotics for combating antibiotic-resistant bacterial infections. The company focuses on harnessing the natural ability of bacteriophages (phages), viruses that specifically target and kill bacteria, to address diseases like cholera. By utilizing phages, PhagePro aims to restore effective treatment options in areas where antibiotic resistance has severely compromised existing medical interventions. This approach offers a potential solution to overcome antibiotic resistance by leveraging a naturally occurring mechanism to eliminate targeted bacteria.
Target Audience
The primary target audience includes individuals in regions affected by antibiotic-resistant bacterial infections, particularly those at high risk for diseases like cholera, as well as healthcare providers and public health organizations seeking alternative treatment options.
Features
- Development of targeted phage therapies for specific bacterial infections.
- Focus on cholera as a lead program to demonstrate the efficacy of phage-based treatments.
- Utilization of naturally occurring bacteriophages to combat antibiotic-resistant bacteria.
- Commitment to addressing health disparities and improving access to effective treatments in underserved communities.